Clinical Trial Update: A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating RO5429083 in patients with metastatic and/or locally advanced CD44-expressing malignant solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• RO5429083

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neoplasms | Phase 1 | Status: COMPLETED